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ABSTRACT
Systematic review methodology is a means of addressing specific questions through structured, consistent, and transparent
examinations of the relevant scientific evidence. This methodology has been used to advantage in clinical medicine, and is
being adapted for use in other disciplines. Although some applications to toxicology have been explored, especially for hazard
identification, the present preparatory study is, to our knowledge, the first attempt to adapt it to the assessment of toxicological
test methods. As our test case, we chose the zebrafish embryotoxicity test (ZET) for developmental toxicity and its mammalian
counterpart, the standard mammalian prenatal development toxicity study, focusing the review on how well the ZET predicts
the presence or absence of chemical-induced prenatal developmental toxicity observed in mammalian studies. An
interdisciplinary team prepared a systematic review protocol and adjusted it throughout this piloting phase, where needed. The
final protocol was registered and will guide the main study (systematic review), which will execute the protocol to
comprehensively answer the review question. The goal of this preparatory study was to translate systematic review
VC The Author(s) 2018. Published by Oxford University Press on behalf of the Society of Toxicology.
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methodology to the assessment of toxicological test method performance. Consequently, it focused on the methodological
issues encountered, whereas the main study will report substantive findings. These relate to numerous systematic review
steps, but primarily to searching and selecting the evidence. Applying the lessons learned to these challenges can improve not
only our main study, but may also be helpful to others seeking to use systematic review methodology to compare toxicological
test methods. We conclude with a series of recommendations that, if adopted, would help improve the quality of the published
literature, and make conducting systematic reviews of toxicological studies faster and easier over time.
Key words: systematic review; test method comparison; zebrafish embryotoxicity test; prenatal developmental toxicity;
malformations.
Toxicology is undergoing a paradigm shift, in which new test
methods are being developed that may contribute to replacing
existing methods that have been used routinely for decades
(Andersen and Krewski, 2009). Over time, researchers exploring a
new method may standardize the protocol and accumulate data
on large numbers of chemicals. An important question to ask is
how well the method serves its intended purpose. For potential
replacement tests, this question typically is addressed by com-
paring the results of the new test with those of the standard test
used routinely for the toxicity of interest, ie, the reference test
method (Hoffmann et al., 2008). When there is a sufficient body of
published literature, questions about test method performance
could potentially be addressed by assessing the available evi-
dence through a literature review (Balls et al., 2006; Corvi et al.,
2008). Such retrospective assessments could be conducted in lieu
of, or as a justification for, prospective validation trials.
Whether concerned with test method performance or other
issues, reviews of the toxicological literature are typically car-
ried out in the form of expert narratives. Typically, narrative
reviews have no clear objective, articulated search strategy, pre-
defined inclusion and exclusion criteria, protocol, or study qual-
ity and risk-of-bias assessment. Such reviews have the benefit
of being relatively economical in manpower and resources in
the short term, but their methodology tends to be fairly ad hoc
and nontransparent, and, therefore, the reviews are potentially
difficult to appraise, interpret, and reproduce (de Vries et al.,
2014). Expert narrative reviews have their place in the contin-
uum of types of published literature summaries, for example,
by generating hypotheses or presenting speculative mechanis-
tic insight that could stimulate creativity and new ideas.
However, where human health or environmental regulatory
decisions are concerned, such as the selection of clinical trial
design, relevant outcome or biomarker, or selection of a test
method to determine toxicity of a new chemical to be used in
the environment, a more systematic approach is warranted.
Here we explore systematic review methodology as a means
of evaluating the performance of a given test method. In con-
trast to narrative reviews, systematic reviews consist of a for-
mal series of steps that starts with the formulation of a specific
question and culminates in the synthesis of the relevant data
from the included papers. Systematic reviews originated in clin-
ical medicine have been standardized for application to clinical
and health care over several decades by Cochrane (Higgins and
Green, 2011), and are now applied in many areas.
Within toxicology, systematic review methodology has be-
gun to be applied to the hazard identification and risk assess-
ment of chemicals (Birnbaum et al., 2013; EFSA, 2010; Johnson
et al., 2014; Rooney et al., 2014), but it has not yet been applied to
the assessment of toxicological test methods (Stephens et al.,
2016). Translating this methodology to other use contexts inevi-
tably involves some adaptation, while retaining the general
approach and adhering to core principles such as transparency,
comprehensiveness, and objectivity (Hoffmann et al., 2017).
Here we present the specific adaptations we found necessary in
the present context of toxicological test methods.
For our test case of applying systematic review methods to
test method performance, we chose the zebrafish embryotoxicity
test (ZET) and its ability to predict the outcomes of the standard
mammalian test for prenatal developmental toxicity. In the ZET,
freshly fertilized zebrafish embryo eggs are exposed to various
concentrations of a test substances added to their aqueous envi-
ronment, usually for up to 120 h post fertilization. During this pe-
riod, embryos are examined for various toxic effects that relate to
mortality, general embryotoxicity (such as hatching rate and
body shape), and specific embryotoxicity (Beekhuijzen et al., 2015;
He et al., 2014; Selderslaghs et al., 2009). Although the principles of
the ZET are largely agreed, protocol details may vary considerably
among studies, which results in a lack of harmonization and
standardization (Hamm et al., 2018). The standard mammalian
test has been standardized as the Organisation for Economic Co-
operation and Development’s Test Guideline 414 (TG 414), which
was first published in 1981 and revised in 2001 and in 2018 (OECD,
2018), and similar national guidelines. In brief, pregnant mam-
mals, most often rats or rabbits, are administered test articles and
toxic effects on fetuses are observed at the end of the gestation
period. The developmental effects observed can be grouped as
growth, external, skeletal, or soft tissue. In addition, variations,
commonly defined as effect diverging beyond the usual range of
structural constitution, which may not adversely affect survival
or health, are discriminated from malformations, commonly de-
fined as permanent structural changes, which may adversely af-
fect survival, development, or function (Chahoud et al., 1999;
Solecki et al., 2003). A further complication is added when mater-
nal toxicity has been observed, which may have been causing or
contributing to the effects observed in the fetuses. This mamma-
lian prenatal developmental toxicity test has drawbacks includ-
ing low throughput, long duration, considerable expense, and
large numbers of animals used (Sipes et al., 2011). These chal-
lenges are being addressed by exploring alternative approaches,
either alone or in combination (Augustine-Rauch et al., 2016; Ball
et al., 2014; Kroese et al., 2015; Panzica-Kelly et al., 2015).
Given the present novel application of systematic review
methodology to the setting of toxicological test method assess-
ment, we first explored methodological issues in this prepara-
tory study. The available chapters of Cochrane’s systematic
review methodology for the assessment of diagnostic test accu-
racy (DTA) were used as a starting point (Cochrane, 2018). We
focus here on the challenges encountered and lessons learned
from this methodological translation. The insights will be ap-
plied to the conduct of the systematic review to comprehen-
sively answer the review question of how predictive the ZET is
of mammalian results, which will be reported elsewhere.
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Acknowledging that systematic review methodology works
best on narrowly defined questions, we focused our comparisons
of effects on developing zebrafish (lethality, general, and specific
embryotoxicity) and mammalian prenatal developmental toxicity
described in external, soft tissue, and skeletal fetal examinations.
Moreover, we translated data on the nature and severity of differ-
ent findings into qualitative outcomes of the presence or absence
of prenatal developmental toxicity. Given these considerations,
we designed our systematic review to answer the following ques-
tion: How well does the presence or absence of treatment-related findings
in the ZET predict the presence or absence of prenatal development toxic-
ity in rats and rabbit studies (OECD TG 414 and equivalents)?
MATERIALS AND METHODS
Review team formation and protocol preparation. This study was ini-
tiated and coordinated by the Evidence-based Toxicology
Collaboration (EBTC) (http://www.ebtox.org/; last accessed June 9,
2019), which is based at the Johns Hopkins Bloomberg School of
Public Health. The EBTC is an international multi-stakeholder or-
ganization that seeks to facilitate the application of evidence-
based approaches—including systematic review—to toxicology.
The EBTC staff invited individuals with relevant expertise from an
existing EBTC working group to join the review team, which un-
dertook the present systematic review. Members were recruited
who could provide the necessary and diverse expertise on mam-
malian reproductive toxicology, zebrafish developmental toxicity,
systematic review methodology, and information science. Care
was taken to recruit individuals from relevant sectors, including
academia, government, industry, and nongovernmental organiza-
tions, which would help to ensure that diverse perspectives were
represented. The members of the review team served as individ-
ual scientists, not as representatives of their organizations or sec-
tors. Their initial charge was to prepare a protocol describing how
the various steps in the review would be carried out.
Search strategy. The goal of the literature search strategy was to
find the full set of chemicals (and their associated studies) that
had been tested in both the ZET and the mammalian prenatal
developmental toxicity test. The review team was familiar
enough with the literature on prenatal developmental toxicity
testing to realize that there was only limited published evidence
directly comparing the results from the ZET and guideline stud-
ies. Consequently, rather than synthesizing pre-existing test
comparisons in the literature, we identified primary studies of
chemicals tested in the ZET or the mammalian assays.
Specifically, the review team developed a 2-stage strategy. We
first searched for ZET studies; after screening and the applica-
tion of our inclusion and exclusion criteria, the resulting in-
cluded studies yielded the identities of the chemicals that were
tested in zebrafish embryos. In the second stage, we searched
the mammalian literature for prenatal developmental toxicity
studies on the same set of chemicals identified in the first stage.
We designed the strategies for both stages to achieve a balance
of precision and comprehensiveness in the results. Search ele-
ments included controlled vocabulary terms (ie, MeSH [Medical
Subject Headings] and Emtree terms), as well as keywords ap-
plied to relevant search fields (title, abstract, descriptors, etc.).
We searched PubMed, Embase (Embase.com), BIOSIS Previews
(Clarivate Analytics), and TOXLINE (National Library of Medicine)
from the earliest available dates to the dates of the searches (see
below). No language limits were applied in the search.
The zebrafish search consisted of a zebrafish concept, a de-
velopmental stage concept, and a toxicity concept. We ran this
search in all 4 databases on April 24, 2014. The mammalian
search consisted of a rat and rabbit concept, an embryo and ma-
ternal concept, and a chemicals concept consisting of the com-
pounds identified through the zebrafish search. We ran this
search in all 4 databases on March 7, 2016. The results of the
zebrafish and mammalian searches were entered into EndNote
for the identification and removal of duplicates. The complete
search strategies are provided as a Supplementary Material.
Screening of zebrafish studies for inclusion and exclusion. Inclusion
and exclusion criteria relating to technical aspects of the zebrafish
studies were difficult to formulate as there has been limited stan-
dardization of the ZET. We used the following inclusion criteria:
• The study reported original data.
• The study was conducted on wild-type zebrafish (Danio rerio) em-
bryos (strain reported).
• Zebrafish embryos were exposed to an individual chemical with
clear identification (eg, chemical name).
• At least 3 chemical concentrations were tested in addition to a
negative/vehicle control group.
• Exposure began no later than 6 h post fertilization (hpf).
• The study was performed for a duration of 48–120 hpf.
• The reported outcomes included mortality, general toxicity (ie,
outcomes related to hatching, cell viability, body shape [general],
edema, the cardiovascular system [heartbeat and blood flow],
and the yolk sac), and specific embryotoxicity (outcomes related
to body shape [specific], fins, skin, the cardiovascular system
[specific, eg, alteration to blood vessels], the central nervous sys-
tem, sensory organs, head, the digestive system, and trunk).
• The study included at least 10 eggs per concentration.
• The study was reported in English.
For the purposes of this preparatory study, we randomly se-
lected a subset of 50 ZET studies, based on the assumption that
this number would yield at least some eligible zebrafish studies.
This was considered sufficient to optimize the search strategy
and the selection process, as well as to develop extraction tables
for the subsequent application in the main study, which was
expected to include thousands of zebrafish studies.
The 50 randomly selected studies were subjected to title and
abstract screening (level 1 screening). The studies that met the
prespecified inclusion criteria and studies for which an inclu-
sion/exclusion decision could not be made from the informa-
tion in the title and abstract alone were carried forward to full
text screening (level 2 screening). At both levels, all studies were
screened by 2 reviewers independently. Conflicts were resolved
between the screeners or, if they could not reach agreement by
themselves, by a third reviewer.
Extraction of data from included zebrafish studies. The chemicals
tested in the included ZET studies were identified and extracted
into the Microsoft Excel table. For each chemical, the informa-
tion specified in the review protocol was extracted into the
same table. This included bibliographic details (first author and
year of publication), study design characteristics (eg, the type of
included controls, species, and strain), intervention characteris-
tics (eg, the chemical name, concentrations tested, and start
and duration of exposure), and outcomes (related to mortality
and morphological alterations). The developmental effects to be
assessed are not yet harmonized in the ZET community (Hamm
et al., 2018). We, therefore, decided on several commonly
reported outcomes, such as mortality, hatching rate and delay,
body shape, edema, and other alterations, to include and






/toxsci/article-abstract/171/1/56/5514546/ by guest on 04 O
ctober 2019
extract, and these were considered sufficient for this adaptation
of systematic review methodology.
Screening of the mammalian studies for inclusion and exclusion. The
literature search for mammalian studies was based on the
chemicals that were extracted from the included zebrafish stud-
ies. The search strings are provided in the Supplementary
Material. We screened the titles and abstracts (level 1 screening)
of the resulting mammalian studies.
The studies that met the inclusion criteria and studies for
which an inclusion/exclusion decision could not be made from
the information in the title and abstract alone were carried for-
ward to full text screening (level 2 screening). At both levels, all
studies were screened by 2 reviewers independently. Conflicts
were resolved between the screeners or, if they could not reach
agreement by themselves, by a third reviewer. Reasons for exclu-
sion were documented. Both levels of screening were carried out
using cloud-based SWIFT-Active Screener software (https://www.
sciome.com/swift-activescreener/; last accessed June 11, 2019).
We used the following inclusion criteria in screening the
mammalian studies:
• The study reported original data.
• The study was conducted on wild-type rats or rabbits (strain
reported).
• Rats/rabbits were exposed to an individual chemical from the in-
cluded zebrafish studies.
• At least 3 doses were administered orally in addition to a nega-
tive/vehicle control group.
• At least 4 pregnant females were treated and reported per group.
• The developing fetuses were examined for death, structural mal-
formations and variations (external, visceral, and skeletal), and
altered growth, as defined and classified by others (Chahoud
et al., 1999; Solecki et al., 2003; Wise et al., 1997).
• The study was reported in English.
Extraction of data from included mammalian studies. For each study-
chemical combination that met the inclusion criteria, data were
extracted from the full texts into a Microsoft Excel extraction ta-
ble, according to the protocol. In addition, information on ma-
ternal toxicity was collected in order to allow for a discussion of
primary embryotoxic effect versus secondary effects potentially
caused by maternal toxicity, if warranted.
Risk of bias. At the time this study was conducted, no risk of bias
guidance or tool that focused on toxicological animal studies
was available. Consequently, we considered tools for animal
studies in general (Krauth et al., 2014) and for preclinical animal
studies, ie, SYRCLE’s risk of bias tool (Hooijmans et al., 2014). We
aimed for a set of risk of bias (and methodological and report-
ing) criteria that would apply equally to both the ZET and the
mammalian prenatal developmental toxicity tests, notwith-
standing that the ZET is clearly not a classical animal test and
that some of its design features are characteristic of in vitro or
ecotoxicological studies, eg, the use of microtiter plates or the
“immersed” exposure in an aqueous environment.
We selected a set of 11 criteria (Table 2). Eight were drawn from
the SYRCLE risk of bias tool (Hooijmans et al., 2014) and 3—report-
ing of randomization, blinding, and sample size calculation—were
the most commonly identified criteria in the Krauth et al. (2014)
systematic review of risk of bias and methodological quality instru-
ments for animal studies. Two reviewers applied the tool to each
study independently, with the assessment options “yes,” “no,” and
“unknown” for the risk-of-bias criteria, and the options “yes” and
“no” for the reporting criteria. Any disagreements were resolved by
discussion between the 2 reviewers, or by third reviewer when
needed.
As information pertinent to these 11 criteria is rarely reported
(Avey et al., 2016; Drucker, 2016; Kilkenny et al., 2009; Leung et al.,
2018), we approached the assessment in a manner we considered
most efficient. When several chemicals and/or species were tested
in a given study, it is recommended to assess the risk of bias for
each species-chemical combination, as aspects pertinent to the
assessment, such as the outcomes reported or the attrition rate,
may differ among such combinations. However, we assumed that
reporting would be consistent for each species-treatment combi-
nation in a study and assessed each study as a whole, instead of
evaluating each species-treatment combination per study.
Data evaluation. Prenatal developmental toxicity hazard, ie, the
potential of a chemical to cause adverse effect that is relevant
for hazard assessment, was considered to be a binary outcome.
Consequently, we tailored evaluation procedures for the ZET
and the mammalian tests according to whether the chemical
was negative (ie, not embryotoxic in the ZET or absence of ad-
verse findings in fetal examination of the mammalian studies,
respectively) or positive (ie, embryotoxic in the ZET or presence
of adverse findings in the fetal examinations of the mammalian
studies, respectively) in a given study.
Data analysis and the presentation of preliminary findings
on test method performance were not the focus of this prepara-
tory study. We refer interested readers to the protocol (Tsaioun
et al., 2018), which specifies the evaluation in detail.
RESULTS
Protocol Preparation and Amendments
The review team produced a working draft of the review proto-
col. Numerous amendments proved necessary, given that this
preparatory study was pioneering the application of systematic
review methodology to the new context of toxicological test
method comparison. All amendments were tracked and incor-
porated into the final protocol, which is being executed in the
main study, and was registered in PROSPERO, an international
prospective register of systematic reviews (CRD42018096120)
(Tsaioun et al., 2018).
Search Results
The results of our literature search for ZET studies are summa-
rized in Figure 1, which follows the PRISMA format (Moher et al.,
2009); 11 741 studies were retrieved from our search. This num-
ber was reduced to 5074 after using EndNote functionality to re-
move duplicates and, for the purpose of this preparatory study,
documents clearly out-of-scope (eg, papers indexed as non-
English and documents without original data, such as research
proposals and meeting abstracts). As planned, 50 of these studies
were randomly selected to explore the applicability of the
adapted methodology. After screening the titles and abstracts of
these studies against our inclusion/exclusion criteria (level 1
screening), 8 papers remained included. After retrieving full texts
of these papers and applying the same criteria (level 2 screening),
1 paper was left. Papers were excluded at each screening level
for a variety of reasons, eg, reporting no prenatal developmental
toxicity outcomes or presenting no original data (Figure 1).
The one included paper by Gao et al. (2014), reported on a
ZET study that assessed 7 chemicals for developmental toxicity
effects, including structural malformations. These 7 chemicals
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were Auranofin (CAS-no. 34031-32-8), Curcumin (CAS-no. 458-
37-7), Gambogic acid (CAS-no. 2752-65-0), Mycophenolic acid
(CAS-no. 24280-93-1), Taxol (CAS-no. 33069-62-4), Thalidomide
(CAS-no. 50-35-1), and Triptolide (CAS-no. 38748-32-2). These
compounds were then used as the chemical concept in the sub-
sequent systematic search of the mammalian literature (see
Supplementary Material). This resulted in 1442 papers being re-
trieved, after removing duplicates; 263 papers remained in-
cluded after level 1 (title and abstract) screening, and 12 of these
papers met our inclusion/exclusion criteria after the level 2 (full
text) review. The reasons for exclusion are reported in Figure 2.
These 12 papers were included in the final analysis.
Test Results
For the 7 chemicals assessed by the included zebrafish study,
acute toxicity, and cardiovascular toxicity, as well as develop-
mental toxicity, were evaluated by Gao et al. (2014). Mammalian
prenatal developmental toxicity data were found on 2 of these
chemicals, namely, gambogic acid and thalidomide. These 2
chemicals caused treatment-related findings in the zebrafish,
ie, missing pectoral fins for both chemicals and reduced pig-
mentation for gambogic acid (Gao et al., 2014).
Of the 12 included mammalian studies, 11 assessed thalido-
mide, and 1 gambogic acid. In these studies, thalidomide was
tested in both rats (2 studies) and rabbits (9 studies), whereas gam-
bogic acid was tested only in rats. Treatment-related adverse
findings of prenatal developmental toxicity were described for tha-
lidomide in both rats and rabbits, and for gambogic acid in rats, for
which no rabbit data were available (Table 1). Among the reported
fetal malformations for thalidomide in rabbits were increased cleft
palate, hydrocephalus, microphthalmia, dysmelia, malrotated
limbs, and spina bifida. In rats, thalidomide was found to have
resulted in prenatal developmental toxicity, such as abnormalities
of the vertebral centrum and the fifth sternal ossification centrum.
For gambogic acid, the prenatal developmental toxicity in the rat
was manifested in an increase of fetal skeletal alterations. The var-
iations reported for this chemical were rudimentary cervical ribs
and delayed skull and sternebral ossifications, as well as retarded
ossifications of vertebra (Table 1).
Given that our search of the mammalian literature yielded stud-
ies with exposures to only 2 out of 7 of these chemicals, ie, thalido-
mide and gambogic acid, we can compare the mammalian prenatal
developmental toxicity results with the ZET results only for these,
which showed treatment-related findings in both species.
Risk of Bias
The risk of bias and the reporting quality of the included zebrafish
(N¼ 1) and mammalian (N¼ 12) papers were assessed (Table 2). For
the 13 studies, the vast majority of the risk-of-bias criteria was
rated as “unknown” (indicated as yellow in Table 2), as the neces-
sary information was not reported. The same holds true for the 3
reporting criteria: with a very few exceptions, none of the relevant
Table 1. Summary of Included Mammalian Studies




Zhao et al. (2010) Rat Sprague Dawley Gambogic
acid
Decrease in fetal weight in the presence of maternal
toxicity. No fetal malformations. Increase in fetal
variations: rudimentary cervical ribs and retarded




Rat Wistar albino Thalidomide No maternal toxicity. No effect on fetal weight.
Decreased litter size based on increased number
of resorptions and stillborn. No fetal malforma-





Rabbit Dutch-belted Tail malformations; malrotated (clubbed ) limbs Positive
Dwornik and Moore
(1965)
Rat Holtzman albino Increased number of abnormal vertebral centra and
vertebrae, increased incidence of absent fifth ster-
nebra and miscellaneous abnormalities like poor
ossification of some or all bones of the pelvis
Positive
Fratta et al. (1965) Rabbit New Zealand Dysmelia Positive
Schumacher et al.
(1968)
Rabbit New Zealand Increased number of limb abnormalities and rib ab-
normalities (no detailed effect description, but as-







Dose-dependent incidence of malformations, in-
creased cleft palate
Positive
McBride (1974) Rabbit New Zealand
white
Fetuses with multiple external malformations (at
high doses; no malformations in control)
Positive
Flohe et al. (1981) Rabbit New Zealand
white
Increased number of malformed fetuses (no more






Increased hydrocephalus; microphthalmia Positive
Sterz et al. (1987) Rabbit Himalayan rabbits Dysmelia Positive
Kawamura et al.
(2014)
Rabbit Kbl: JW rabbits Malrotated paws; ectrodactyly, brachydactyly Positive
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information was reported (indicated as red in Table 2). There was
no substantive difference observed between the risk of bias in the
mammalian studies and the zebrafish study. Although the number
of studies was small, it is worth noting that there was no obvious
trend in the more recent mammalian literature toward more de-
tailed reporting, as the older studies were equally likely (or not) to
contain the information.
Challenges and Lessons Learned
In addition to the preparation of the protocol that adapts sys-
tematic review methodology to toxicological test method as-
sessment, we consider the identification of the challenges
encountered and the lessons learned as the primary result of
this preparatory study. Here we provide an annotated listing of
these challenges and lessons learned, organized under the
headings of the typical steps of a systematic review.
Formulating the question.
• As outcomes in zebrafish and mammals cannot be compared di-
rectly due to differences in anatomy and embryogenesis, we chose
embryotoxicity in zebrafish and prenatal developmental toxicity in
mammals as nonspecific outcomes that subsume various effects.
This broadness in the review question was necessary to render out-
comes of the test methods comparable, but it also presented a chal-
lenge in several of the subsequent review steps.
Searching the evidence.
• In the absence of studies that tested the same chemicals in par-
allel in both tests, a novel 2-stage strategy was devised, first to
identify studies that tested chemicals in the ZET and, second, to
identify studies that tested the same chemicals in mammalian
prenatal developmental toxicity studies.
• Fine-tuning of the search strategy was made difficult by the fact
that MeSH terms in MEDLINE/PubMed are oriented towards clini-
cal medicine, and do not capture the relevant fields for toxicol-
ogy (see eg, https://www.nlm.nih.gov/mesh/meshhome.html/
last accessed June 11, 2019).
Selecting the evidence.
• Due to the lack of structured abstracts in the screened literature,
it was often challenging to identify the information pertinent to
the inclusion and exclusion criteria, which considerably slowed
down the efficiency of identifying relevant studies.
• Substantial diversity in reported ZET outcomes, likely a conse-
quence of the lack of protocol harmonization in the field, compli-
cated the identification of relevant studies.
Extracting data.
• Data extraction was made difficult by the lack of a commonly ac-
cepted ontology for adverse outcomes in zebrafish studies and,
in general, by a failure to use a controlled vocabulary for report-
ing study information.
Analyzing data.
• Several challenges, some of which have been mentioned above,
compelled us to adopt a simplified approach to data analysis, fo-
cusing on the presence or absence of any kind of structural alter-
ations. All efforts to make these considerations as transparent
and rational as possible were undertaken and are explained in
the protocol (Tsaioun et al., 2018).
Reporting.
• We observed that the published study reports in our sample
were inadequately reported to fully assess risk-of-bias and
Figure 1. Preferred reporting items for a systematic review and meta-analysis (PRISMA) flow diagram for the zebrafish studies retrieved from the literature search (hpf:
hours post fertilization).
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methodological quality (Table 2), which suggests that this may
be the case throughout this literature. This would be consistent
with the finding of poor quality of reporting of experimental ani-
mal studies, both observed by other reviews related to toxicology
(Koustas et al., 2014; NTP, 2016) and in the literature of preclinical
animal studies (Freedman et al., 2017; Sena et al., 2014; Tihanyi
et al., 2019).
DISCUSSION
Clinical medicine has pioneered systematic review methodol-
ogy (Chandler and Hopewell, 2013). This methodology is being
adopted and adapted to other scientific disciplines such as envi-
ronmental health science (Rooney et al., 2014, 2016 and Sutton,
2014), preclinical animal studies (Hirst et al., 2014; Yauw et al.,
2015), and other fields (Okoli and Schabram, 2010) because of its
structured framework, transparency, comprehensiveness, re-
producibility, and objectivity. This preparatory study’s goal was
the translation of systematic review methodology to a new use
context: the assessment of test method performance in toxicol-
ogy. Consequently, we focused on the methodological issues
encountered, whereas the main study will report substantive
findings.
The methodological translation proved feasible but raised a
number of issues and presented numerous challenges. Before
discussing these, we briefly comment on the relevance of this
preparatory study to the review question, concerning the ability
of the ZET to predict prenatal developmental toxicity in the
mammalian guideline studies. First, the results of the literature
search indicate that there is a substantial literature on the test-
ing of chemicals in both sets of tests (Figs. 1 and 2).
Extrapolating the inclusion ratio of 1 in 50 studies from this pre-
paratory study to the main study with several thousand ZET
studies, it can be expected that approximately 100 studies may
be included in the main study. As these will have tested several
hundred chemicals, many of which will also have eligible
mammalian prenatal developmental toxicity studies, it can be
expected that the main study will be based on a substantial
amount of evidence. A second noteworthy finding was the poor
reporting, resulting in an unknown risk of bias in the included
individual studies (Table 2). Projected to the main study, this
may limit the level of confidence in the review’s conclusions.
Since the time this study was conducted, several critical ap-
praisal tools focused on toxicology/environmental health have
been be published (Beronius et al., 2018; Rooney et al., 2014;
Woodruff and Sutton, 2014). To the extent that these tools as-
sess risk of bias, they basically address the same bias domains
as were assessed here and would have led to largely the same
conclusions regarding risk of bias in the studies included here.
As a consequence, the risk-of-bias assessment will be reconsid-
ered in relation to other factors that potentially influence the
confidence in results of individual studies, such as the physical-
chemical properties of chemicals, eg, low water solubility, that
may lead to reduced exposure in the ZET, or the interpretation
of adverse effects in the mammalian studies in the presence of
maternal toxicity. Third, using the nonspecific outcome of
embryotoxicity in the ZET and prenatal developmental toxicity
in mammals, results of the ZET and the mammalian prenatal
developmental toxicity tests were comparable. However, the
small number of chemicals, which resulted from our methodo-
logical focus, did not—as expected—allow us to draw any sound
conclusions regarding the performance of the ZET. This prepa-
ratory study, in particular the developed protocol, has provided
the methodology to be used for the main study, which will eval-
uate all evidence obtained from the literature search. This is
expected to result in a sufficiently large number of chemicals to
compare the test methods and calculate predictive performance
parameters.
As this study was the pioneering effort to adapt the system-
atic review framework to the context of test method assess-
ment, we made a few decisions to facilitate—and learn from—
this transition. First, we focused our comparisons on
Figure 2. Preferred reporting items for a systematic review and meta-analysis (PRISMA) flow diagram for the mammalian studies retrieved from the literature search.
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embryotoxicity in vitro and prenatal developmental toxicity
in vivo only, setting aside potential comparisons of other ad-
verse developmental effects, such as developmental neurotoxic
outcomes. In the future, the test methods could be more fully
compared in a comprehensive systematic review with subgroup
analyses, eg, focusing on specific outcomes or group of out-
comes. Second, within our chosen domain, we translated data
on the nature and severity of embryotoxicity in the ZET and pre-
natal developmental toxicity in mammals into qualitative out-
comes of the presence or absence of treatment-related
alterations. And finally, we limited the mammalian prenatal de-
velopmental toxicity studies to those involving rats or rabbits,
given that these species have been more commonly used than
other species.
These decisions resulted in the following main study review
question: How well does the presence or absence of treatment-
related findings in the ZET predict the presence or absence of
prenatal development toxicity in rats and rabbit studies (OECD
TG 414 and equivalents)? In systematic review terminology, this
is fundamentally a PECO question design (eg, Morgan et al.,
2018; Woodruff and Sutton, 2014)—that is, the question
addresses the Populations (exposed zebrafish embryos, rats,
and rabbits fetuses), Exposure (to individual chemicals),
Comparison (comparator test: rats/rabbits prenatal develop-
mental toxicity test), and Outcome (embryotoxicity). Simply
put, the review compares the embryotoxicity hazards of chemi-
cals in the ZET with the prenatal developmental toxicity ob-
served in rats and rabbits. The outcomes included in this
question were broad. They covered many morphological altera-
tions of the embryos in the ZET as well as many morphological
alterations in external, soft tissue, and skeletal fetal examina-
tions specific for mammalian prenatal development, which are
due to species differences not directly comparable. In contrast,
questions should be narrow to make them amenable to system-
atic review (Hoffmann et al., 2017). Therefore, the comparison of
test methods that provide information on a broad range of out-
comes that all inform the same hazard is a fundamental chal-
lenge that causes problems in the subsequent systematic
review steps, eg, for the study selection (What is the minimum
set of outcomes that a study must report to be eligible?) and for
the data analysis (How to summarize repeat studies of the same
chemical?). These aspects should be thoroughly considered
when embarking on a systematic review to compare toxicologi-
cal test methods.
We faced some challenges when translating our PECO ques-
tion into database search strategies, notably when generating
toxicology-related search terms from PubMed’s controlled vo-
cabulary MeSH. Although we identified a number of relevant
MeSH terms for our search (eg, “Toxicity Tests”[Mesh]), we
found a general lack of robustness in MeSH’s coverage of toxi-
cology. We addressed this challenge by carefully including rele-
vant keywords in our PubMed search and by running our search
in multiple databases. Because of their unique features, these
other databases added results not found by PubMed. For in-
stance, Embase has its own controlled vocabulary that
addresses toxicology with more robustness, and TOXLINE has
an explicit focus on the toxicological literature.
Our starting point in this preparatory study was the method-
ology for a standard systematic review as used in clinical medi-
cine, as suggested by Hartung (2010). Led by Cochrane, clinical
medicine has pioneered systematic review methodology in the
context of assessing the effectiveness of “interventions” such as
new drugs or surgical techniques (Chandler and Hopewell,
2013). Cochrane is currently translating systematic review
methodology to the assessment of DTA, a context that has
some parallels to assessing test methods in toxicology
(Hoffmann and Hartung, 2005, 2006). Cochrane has been pub-
lishing chapters of its Handbook for DTA Review online as they
become available (Cochrane, 2018). Although intended for a dif-
ferent context, this emerging Handbook was helpful to the pre-
sent study in a number of areas, especially in protocol
preparation and terminology. However, the parallels between
this clinical situation (assessing DTA) and the toxicological situ-
ation (assessing test performance) are limited in practice. For
example, in the clinical situation, the reviewed studies are
themselves direct comparisons of the diagnostic tests under re-
view, thus rendering the review essentially a compilation of
pre-existing comparisons, as reflected, for example, in the pre-
ferred reporting items for a systematic review and meta-
analysis (PRISMA) for studies of diagnostic test accuracy
(McInnes et al., 2018). In the toxicology context, however, the
studies relevant for comparison of 2 toxicological test methods
are typically studies of individual chemicals in one or the other
test, but not studies comparing both.
In addition, this effort should be put in the larger context of
applying systematic review methodology to the evaluation of
toxicological studies for environmental health questions and in
chemical risk assessment (Rooney et al., 2014; Whaley et al.,
2016; Woodruff and Sutton, 2014). This application commonly
takes the form of reviewing the evidence that associates chemi-
cal exposure with a specific health effect (see eg, Cano-Sancho
et al., 2017; Koustas et al., 2014; NTP, 2016). Although the number
of such systematic reviews is increasing, the adaptation of the
systematic review methodology for this purpose still faces chal-
lenges, such as rating the confidence in the body of evidence or
integrating the evidence from human, animal, and nonanimal
studies (Morgan et al., 2016). Although the PECO questions of the
2 systematic review applications (exposure effects vs test
method comparisons) are substantially different, close connec-
tions of these 2 applications are evident in other review steps.
Literature sources will be similar and some search concepts, eg,
for the exposure (chemicals and their synonyms) and for out-
comes, are required for both applications. In addition, eligibility
criteria related to study design are likely to be similar, as both
applications are usually based on studies that fulfill at least ba-
sic design requirements, as are approaches to critical appraisal
of studies. In contrast, rating the confidence in the body of evi-
dence will differ in some regards, as aspects such as consis-
tency, precision, and effect size are not directly applicable to
test method comparisons. In addition and as in the clinical field,
data analysis approaches will not have any great similarity.
We conclude with several recommendations that stem from
the challenges and lessons identified above.
• MeSH search terms: The terminology and hierarchy of MeSH
search terms in PubMed should be expanded to provide more
utility to toxicology.
• Structured abstracts: Toxicology journals should consider requir-
ing structured abstracts that call for critical types of information
to be present, labeled, and listed in a certain sequence, as has
been called for in clinical studies (Mulrow et al., 1988). An addi-
tional advantage of structured abstracts is that they are more
amenable to automated approaches, such as machine-reading.
• Completeness of reporting: Methodological details and study results
should be reported in sufficient detail to permit readers to assess
how confident to be in the results and conclusions, as well as
how to replicate a given study (Avey et al., 2016; Drucker, 2016;
Kilkenny et al., 2009; Leung et al., 2018). Numerous guidelines are
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available for reporting quality, see eg, Samuel et al. (2016). Also,
improved and comprehensive reporting of studies in toxicologi-
cal databases would be helpful and could ultimately qualify
them as eligible evidence sources for systematic review
purposes.
• Risk of bias: As already called for by Rooney et al. (2016), studies
providing empirical evidence on the impact of individual biases
on toxicological evidence should be conducted. Once a bias has
been demonstrated to be influential in the toxicological litera-
ture, concrete steps could be taken to minimize such potential
biases in experimental studies not only by the researchers, but
also by organizations conducting, commissioning and funding
the studies, and by regulatory agencies. In addition, the impor-
tance of the risk-of-bias assessment needs to be assessed in rela-
tion to how other factors, such as external validity, potentially
influence conclusion.
• Ontologies/controlled vocabularies: An ontology and/or controlled
vocabulary can expedite the systematic review process (by
streamlining data compilation), and ultimately, can make
machine-learning and data-mining approaches possible (Hardy
et al., 2012a,b). An ontology and/or controlled vocabulary should
be developed (or aligned to an existing) as early in the develop-
ment of a new test method as is appropriate, which is especially
important for test methods with many potential outcomes and
those that involve organisms or tissues more distantly related to
those used routinely.
If followed, these recommendations would not only facili-
tate the conduct of systematic reviews, but also promote the
broader goal of producing reliable science to inform regulatory
decisions.
In conclusion, we argue that systematic reviews of the as-
sessment of toxicological test methods are feasible, although
challenging. A practical prerequisite for a definitive systematic
review in this context, as in others, is that sufficient relevant ev-
idence is publicly available, which might not be the case for ev-
ery new toxicological test method. Some systematic reviews
have value in documenting the limited extent of available evi-
dence, and thus flagging a data gap. However, it is difficult to as-
sess whether the toxicological community would be well served
by a full-blown systematic review of test method comparisons
that simply flagged a data gap; other approaches are better
suited, eg, evidence maps (Miake-Lye et al., 2016). Moreover,
there should be data of sufficient detail and quality in the rou-
tinely used species (or human outcomes), retrievable by a sys-
tematic literature search, in order to provide a basis for
comparison of the new tests. For regulatory evaluations in the
future, one could envision test developers submitting detailed
information about the mechanistic basis of a new test (Hartung
et al., 2013), along with a dataset exhibiting low risk of bias. It
could then be compared to the outcomes of the standard guide-
line test and human outcomes, both obtained through system-
atic literature searches.
It is acknowledged that the comparison of 2 test methods
will be increasingly replaced by comparing combinations of test
methods against a single or composite reference standard. Such
combinations of various test method and other information, for
example in testing strategies and integrated approaches to test-
ing and assessment, will be essential, for example, in imple-
menting Toxicity Testing in the 21st Century (NRC, 2007). The
challenges in designing and assessing such strategic
approaches have been identified, but the discussions of solu-
tions continues (Jaworska and Hoffmann, 2010; Piersma et al.,
2018; Rovida et al., 2015). The complexity goes far beyond the
direct comparison of 2 test methods for the same purpose as
planned in our review, which has successfully been used for so-
called one-to-one replacements of in vivo test method by a non-
animal test method (see eg, Spielmann et al., 2007). However, as-
suming that a performance assessment will also be required for
testing strategies, a systematic review approach could be
equally applied. Therefore, our methodological adaptation to
one-to-one comparisons will also be of value for more complex
situations. For example, test methods addressing the same
mechanistic event could be compared systematically or a com-
bination of test methods could be compared to reference results
(Kleinstreuer et al., 2018).
Although it can be anticipated that a substantial effort is re-
quired to assess toxicological test methods, either individually
or in combination, the advent of artificial intelligence (AI) and
machine learning (ML) bears the promise of increasing effi-
ciency, ultimately enabling updates of existing systematic
reviews in real time. This will make this application much more
pragmatic, as compared to prospective studies, eg, when for-
mally validating test methods according to international
requirements (Hartung et al., 2004; OECD, 2005). In addition, var-
ious methodological challenges remain that call for the adapta-
tion of existing methodology, if not for new approaches. The
necessary methodological solutions should adhere to the fun-
damental evidence-based principles of transparency, objectiv-
ity, and consistency, and should be agreed on by all interested
stakeholders. As these solutions are developed, systematic re-
view may become a standard tool for the retrospective evalua-
tion of toxicological test methods.
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